NAD tells Metabolic Research to drop claims
This article was originally published in The Tan Sheet
Metabolic Research disagrees with the National Advertising Division's recommendations to discontinue claims that people who take Stemulite experience "deep REM sleep, Increased Muscle Gain and Endurance, Increased Wellness and Energy." The firm said data in the New England Journal of Medicine and "similar resources" supports the claims. It added it "retained counsel to further review" claim documentation and has "every intention" of complying. NAD said a 17-person, 30-day study Metabolic Research submitted did not support the claims because it was too small, subjective and not placebo-controlled. The two got off to a rocky start when NAD attempted to contact the firm via a former employee at an incorrect address. The resulting delay did not give the firm enough time to response to NAD's request, the firm said. This prompted NAD to refer the case to the Federal Trade Commission (1"The Tan Sheet" Sept. 7, 2009). NAD reopened the case after the advertiser said it would participate
You may also be interested in...
Stemulite fitness dietary supplements marketer Metabolic Research Inc. finds that failing to reply promptly to a National Advertising Division inquiry can get a firm tossed from the self-regulatory frying pan into the FTC fire
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.